MoonLake Immunotherapeutics (MLTX) Prices 8M Share Offering at $50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
June 28, 2023 5:00 AM EDTMoonLake Immunotherapeutics Announces Pricing of $400 Million
Upsized Public Offering of Class A Ordinary Shares
ZUG, Switzerland, June 28, 2023 MoonLake Immunotherapeutics (Nasdaq: MLTX) (MoonLake), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced the pricing on June 27, 2023 of its upsized underwritten public offering of 8,000,000 Class A ordinary shares at a public offering price per share of $50.00. The gross... More
